TY - JOUR
T1 - Practical guidance to insulin management.
AU - Meneghini, Luigi
AU - Artola, Sara
AU - Caputo, Salvatore
AU - Damci, Taner
AU - Dzida, Grzegorz
AU - Kaiser, Marcel
AU - Khunti, Kamlesh
AU - Liebl, Andreas
AU - Ligthelm, Robert
AU - Maran, Alberto
AU - Orozco-Beltran, Domingo
AU - Ross, Stuart
AU - Yale, Jean François
N1 - Funding Information:
All authors have been involved throughout the development of the practical guidance, from initial concept to providing final approval. At an international meeting, held in May 2009, 130 expert physicians gave their feedback on what important information should be included in a practical guidance for insulin management to formulate a ‘call to action’. The feedback was reviewed by the authors, and the content of the practical guidance developed. The meeting upon which the content of this practical guidance is based was funded by Novo Nordisk. The authors are all members of a Novo Nordisk advisory board, for which they are paid an honorarium. Medical writing assistance and layout concept support was provided by Eleanor Steele and Gary Burd at Complete HealthVizion; this assistance was funded by Novo Nordisk, who also had a role in the review of the practical guidance for scientific accuracy.
Funding Information:
Luigi Meneghini has received funding for research from Novo Nordisk, sanofi-aventis and Medtronic Minimed, has acted as a consultant to Novo Nordisk, is a member of an advisory board for Novo Nordisk, and is a member of a speaker bureau for Novo Nordisk, Eli Lilly and sanofi-aventis. Sara Artola has received honoraria from Novo Nordisk, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Servier, sanofi-aventis and Eli Lilly, is a member of advisory boards for Novo Nordisk, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Servier, sanofi-aventis and Eli Lilly, and has received research funding from Novo Nordisk, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Servier, sanofi-aventis and Eli Lilly. Salvatore Caputo has received honoraria from Eli Lilly, GlaxoSmithKline, Merck Sharp & Dohme, Novo Nordisk and Takeda, has received consulting fees from Eli Lilly, GlaxoSmithKline, Merck Sharp & Dohme, Novo Nordisk and Takeda, and has received funding for research from Eli Lilly, GlaxoSmithKline, Merck Sharp & Dohme, Novo Nordisk and Takeda. Taner Damci has received honoraria from Novo Nordisk, Lilly, sanofi-aventis, Merck Sharp & Dohme, Bristol Meyer Squibb, Servier, AstraZeneca, Abbott, Roche, Roche Diagnostics, Bilim Ilac¸, Sanovel, Eczacibaus¸i. Grzegorz Dzida is a member of an advisory board for Novo Nordisk. Marcel Kaiser owns stocks of Novo Nordisk and is a member of an advisory board for Novo Nordisk. Kamlesh Khunti has received funding for research from Lilly, MSD, Novartis, Novo Nordisk, Pfizer, sanofi-aventis and Unilever and has acted as a consultant to or received honoraria from AstraZeneca, BMS, Lilly, MSD, Novartis, Novo Nordisk, Pfizer, sanofi-aventis, Takeda and Unilever. Andreas Liebl has received honoraria for presentations from Eli Lilly, MSD, Roche, and Novo Nordisk, and is a member of
Funding Information:
advisory boards for Eli Lilly, MSD, Roche, and Novo Nordisk. Robert Ligthelm is a member of advisory boards for Novo Nordisk, Eli Lilly and GlaxoSmithKline and has received funding for research from Novo Nordisk, GlaxoSmithKline, Pfizer, Novartis and sanofi-aventis. Alberto Maran has received honoraria from Novo Nordisk. Domingo Orozco-Beltran has received research funding from Novo Nordisk, Merck Sharp & Dohme, Eli Lilly, GlaxoSmithKline and sanofi-aventis and has been a member of advisory boards for Novo Nordisk, Merck Sharp & Dohme, Eli Lilly, GlaxoSmithKline and sanofi-aventis. Stuart Ross has received honoraria from Novo Nordisk and funding for research from Novo Nordisk, and is a member of an advisory board for Novo Nordisk. Jean-Franc¸ois Yale has received honoraria from Eli Lilly, Novo Nordisk and sanofi-aventis and is a member of advisory boards for Eli Lilly, Novo Nordisk and sanofi-aventis.
Funding Information:
All authors have been involved throughout the development of the practical guidance, from initial concept to providing final approval. The meeting upon which the content of this practical guidance is based was funded by Novo Nordisk. The authors are all members of a Novo Nordisk advisory board, for which they are paid an honorarium. Medical writing assistance and layout concept support was provided by Eleanor Steele and Gary Burd at Complete HealthVizion; this assistance was funded by Novo Nordisk, who also had a role in the review of the practical guidance for scientific accuracy.
PY - 2010/4
Y1 - 2010/4
N2 - The practical guidance to insulin management is a simple tool for health care providers, particularly primary care physicians (PCPs). Developed by experts in diabetes care at an international meeting, it aims to help physicians make key decisions to optimize insulin management and decrease long-term morbidity risk. With a growing role for PCPs in type 2 diabetes, the practical guidance focuses on confident, appropriate and timely insulin initiation. Using the acronym 'TIME' (Targets, Insulin, Managing weight, Encouragement and support) the practical guidance aims, in a visually appealing format, to help physicians address the challenges of insulin management with their patients, from diagnosis through insulin initiation to follow-up. 2010 Primary Care Diabetes Europe. Published by Elsevier Ltd.. All rights reserved.
AB - The practical guidance to insulin management is a simple tool for health care providers, particularly primary care physicians (PCPs). Developed by experts in diabetes care at an international meeting, it aims to help physicians make key decisions to optimize insulin management and decrease long-term morbidity risk. With a growing role for PCPs in type 2 diabetes, the practical guidance focuses on confident, appropriate and timely insulin initiation. Using the acronym 'TIME' (Targets, Insulin, Managing weight, Encouragement and support) the practical guidance aims, in a visually appealing format, to help physicians address the challenges of insulin management with their patients, from diagnosis through insulin initiation to follow-up. 2010 Primary Care Diabetes Europe. Published by Elsevier Ltd.. All rights reserved.
UR - http://www.scopus.com/inward/record.url?scp=77954920323&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954920323&partnerID=8YFLogxK
U2 - 10.1016/S1751-9918(10)60008-3
DO - 10.1016/S1751-9918(10)60008-3
M3 - Article
C2 - 20394891
AN - SCOPUS:77954920323
SN - 1751-9918
VL - 4 Suppl 1
SP - S43-56
JO - Primary care diabetes
JF - Primary care diabetes
ER -